MILAN, July 14, 2015 /PRNewswire/ --
The deal will speed up the commercialization of Xadago® for the treatment of Parkinson's Disease
Nigaard is a pharmaceutical company well established in Denmark, Norway, Sweden, Iceland and Finland
Zambon S.p.A., an international pharmaceutical company strongly committed to the Central Nervous System (CNS) therapeutic area and the Respiratory area with a focus on Rare Diseases, announced today the acquisition of Nigaard, a full service specialised company headquartered in Oslo, Norway.
(Logo: http://photos.prnewswire.com/prnh/20150515/744259 )
Established in 2002, Nigaard is a licensed pharmaceutical company focused on Respiratory and Allergy, including pharmaceuticals and medical devices, well developed in all the countries of Northern Europe: Denmark, Norway, Sweden, Iceland and Finland. It is currently Promixin® distributor for Sweden and Norway, as well as owner of several distribution and licensing agreements.
With the acquisition of Nigaard, that follows the Profile Pharma deal in UK in 2013 and the re-establishment of a branch in Germany in 2014, Zambon is now covering all the Western Europe markets.
Maurizio Castorina, CEO of Zambon SpA stated: "The Nordic countries are very interesting for the investments' plan of Zambon both because of the high standards on Healthcare System and the dimension of the market, with a population of 25 million. Nigaard is a well-known organization with an important capillarity in Northern Europe and its acquisition is an important step forward to speed up the commercialization of Xadago®, for the treatment of Parkinson's Disease, and the development of Promixin®, our inhaled antibiotic for bronchial infections in Cystic Fibrosis. The expansion of Zambon will also increase our professional competences in the specialties business as key success factor."
Zambon Regional General Manager for Northern & Central Europe, Roberto Antonini, also commented: "We have the great opportunity to approach the Scandinavian region with a full control of regulatory, distribution and promotional affairs. Nigaard people have the right skills and competences and this acquisition will also boost our internationalization process after UK in 2013 and Germany last year."
About Zambon
Zambon is a leading Italian pharmaceutical and fine-chemical multinational business with a strong reputation for high quality products and services. The Group is strongly working on the treatment of the chronic respiratory diseases as asthma and COPD and on the CNS therapeutic area with Xadago® (safinamide), licensed by Newron, for the Parkinson treatment. Zambon is also well-established in 3 therapeutic areas: Respiratory, with a focus on Rare Disease and in particular on Cystic Fibrosis, Pain and Women's care. Zambon SpA produces high quality products thanks to the management of the whole production chain which involves Zach (Zambon chemical), a privileged partner for API, custom synthesis and generic products. Headquartered in Milan and established in 1906 in Vicenza, Zambon has branches in 15 countries and more than 2,600 employees with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon products are commercialized in 73 countries.
For details on Zambon please see: http://www.zambongroup.com
About Nigaard
Nigaard was created in 2002 in Oslo by Kjetil Herland. After some 25 years working mainly in large pharma companies in the Nordic area, he decided to start a new full-service pan Nordic distribution company focusing on Respiratory diseases and allergy. Since the beginning, the company has formed a small-specialized team, built good access to key opinion leaders and a majority of the key specialized doctors, established a growing reputation as a good Nordic partner and secured the distribution rights for products in the Nordic area. Nigaard provides full service, pan-Nordic market access for large international Pharmaceutical companies.
For further information
Media
Zambon
CCO
Luca Primavera
Phone: +39-02-66524491
Mobile: +39-335-7247417
Email: luca.primavera@zambongroup.com
Germana Mancino
Email: gmancino@webershandwick.com
Ph: +39-3492625439
Weber Shandwick
Share this article